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OBJECTIVES: To examine the clinical and economic impact of diagnostic-driven 
(DD) versus empiric treatment strategies in neutropenic patients with suspected 
Aspergillus invasive fungal infections (IFIs) in Beijing, Chengdu, and Guangzhou, 
China. METHODS: A decision-analytic model was used to estimate total costs 
and survival associated with a DD and empiric treatment strategy for managing 
suspected IFIs in adult patients with neutropenia due to hematological malig-
nancy or autologous/allogeneic stem cell transplant. In the DD strategy, IFI was 
identified via serum galactomannan (GM) enzyme-linked immunosorbent assay 
(ELISA) so that early initiation of targeted treatment could be administered. IFI 
incidence (10.9%), portion of actual IFIs diagnosed via empiric treatment (30%), 
overall mortality (10.7%), and IFI-related mortality (28.6%) were obtained from 
the literature. Survival rates were generated based on the proportion of patients 
with identified and appropriately treated IFIs. Empiric and DD treatment pat-
terns and resource use were based on clinical opinion (3-5 clinicians from top 
hospitals per city). Medical costs (in 2014 Chinese Yuan [¥]) included antifungal 
drugs, treatment-related adverse events, and other medical resource costs. City-
specific costing sources were used wherever possible. RESULTS: Medical costs 
were lower for the DD versus the empiric strategy in Beijing (¥4,118 vs ¥5,245), 
Chengdu, (¥5,463 vs ¥6,389), and Guangzhou (¥9,762 vs ¥10,351). Fewer patients 
received antifungal treatment using the DD strategy (6.7% versus 11.4%), and sur-
vival rates were similar. One-way sensitivity analysis showed results were most 
sensitive to changes in GM test sensitivity followed by IFI incidence. Probabilistic 
sensitivity analysis showed that treating via a DD strategy was dominant 99% of 
the time. CONCLUSIONS: These results suggest that in China, a DD strategy to 
identify IFIs in immunocompromised patients with persistent fever in order to 
better target antifungal treatment compared to an empiric antifungal treatment 
strategy may be cost-saving, while maintaining a similar overall survival rate.
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OBJECTIVES: We aimed to assess cost-effectiveness of ceftaroline fosamil (CF) for 
treatment of hospitalised patients with pneumococcal community-acquired pneu-
monia (PCAP) in Russia from societal perspective. METHODS: Decision tree model 
based on results of two 3rd phase clinical trials (FOCUS1/FOCUS2) was created to 
assess clinico-economic implications of PCAP treatment with CF vs. ceftriaxone 
(CS) for society. Day 4 early clinical response (73% vs. 56%, p= 0,03) was taken for 
effectiveness outcome. Direct and indirect expenses associated with initial episode, 
possible recurrence of PCAP, direct and delayed attributive mortality were taken into 
consideration. Original drugs costs were extracted from wholesale prices database 
(www.pharmindex.ru). Cost of therapy was calculated to correspond treatment regi-
ments in selected trials: CF 600mg BID vs. CS 1g QD and common in Russia CS 2g 
QD. Alternative treatment in case of inefficacy was chosen per experts’ opinion. 
Indirect expenses evaluation was based on human capital approach (loss in GDP per 
capita) with 5% discount rate per year. All expenses were converted to US dollars at 
exchange rate on the date of calculation (June 2014). Uncertainty was explored in 
a series of one- and two-way deterministic and in probabilistic sensitivity analy-
sis. RESULTS: Respective total expenses of PCAP treatment with CF 600mg BID vs. 
CS 1g vs. CS 2g QD were as follows: $16548.6 vs. $16894.4 vs. $16972.3, making CF 
strategy the dominating one. Results were sensitive to change in rate of early clini-
cal response to comparators and duration of CF course. Given willingness-to-pay 
$12.8 per additional 1% of clinical response (per experts’ opinion) 95.1% and 97.3% 
of iterations in probabilistic sensitivity analysis recommended CF over CS 1g or 
2g QD for treatment of PCAP. CONCLUSIONS: CF 600mg BID is more cost effective 
then CS 1g or 2g QD in the treatment of hospitalised patients with PCAP in Russia 
from societal perspective.
PIN57
EcoNomIc ImPAct of sImulAtIoN-BAsED trAININg (sBt) for cENtrAl 
VENous cAthEtEr (cVc) INsErtIoN
Asche C.V.1, Barker L.2, Ren J.1, Kim M.1, Kirkness C.S.1, McGarvey J.2, Short J.2, Vozenilek J.2
1University of Illinois College of Medicine at Peoria, Peoria, IL, USA, 2Jump Trading Simulation & 
Education Center and the OSF Healthcare, Peoria, IL, USA
OBJECTIVES: CVC insertion is one of the most commonly performed medical pro-
cedures in the intensive care hospital setting. The clinical impact of SBT in the 
procedure has been demonstrated previously. However, little is known about the 
economic impact of such educational interventions. This study aimed to analyze 
the costs associated with outcomes attributable to the implementation of a SBT 
program for CVC insertion. METHODS: The SBT training interventions were imple-
mented for residents working in the MICU at OSF St. Francis Medical Center in 
Peoria, Illinois, from 09/01/2012 to 12/31/2013. Data from an historical control group 
(traditional training) was selected during a parallel time period from 09/01/2010 to 
12/31/2011. Collected information included total hospital cost, training cost, LOS, 
complications, and patient demographics. Costs were adjusted to 2014 dollars. 
Adjusted generalized linear models were used to estimate the margin effects for the 
cost and the effectiveness. RESULTS: 86 residents placed 353 CVC lines in patients 
three years (iPREX trial). The study objective was to estimate the cost-effectiveness 
of PrEP (Emtricitabine-Tenofovir combination pill) from the US payer perspective 
using both short-run and long-run outcomes. METHODS: We designed a decision 
analytical model using Excel® 2013 that mimicked the iPREX trial environment 
to compare costs and outcomes of PrEP plus usual care versus usual care alone 
(i.e. condom use). Outcomes included HIV cases averted over the trial period of 
3 years and life years gained (LYG) over a lifetime time horizon. Since the adher-
ence of PrEP was an important outcome measure in the trial, we factored in the 
PrEP adherence relationship of HIV acquisition into the model. Condom effective-
ness was defined as probability of remaining HIV negative, assuming consistent 
condom usage. All costs were adjusted to 2014. RESULTS: From our base-case 
analysis, the treatment arm (PrEP plus usual care) resulted in an incremental cost 
of $ 1,369,784 per HIV case averted over a 3-year time frame and an incremental 
cost of $ 34,973.50 per LYG over a lifetime time horizon. Our one-way sensitiv-
ity analysis suggested that condom effectiveness below 92% can make PrEP to 
be cost-saving per LYG. Our probabilistic sensitivity analysis suggested that the 
cost-effectiveness probability of PrEP is at least 50% if the payer is willing to pay 
a minimum of $45,000-$50,000 per LYG. CONCLUSIONS: The short-run value of 
PrEP from the US payer perspective may be greater than their willingness-to-
pay. Further research is warranted to understand subgroups where PrEP value 
differs as well as payers’ willingness-to-pay for HIV-specific and generic health 
outcomes.
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OBJECTIVES: An estimated 35 million people were living with HIV around the 
world in 2012. Although a toolbox of prevention methods including condoms, 
risk reduction counseling, voluntary circumcision, pre-exposure prophylaxis, and 
more are available, the development of an HIV vaccine is seen as the only hope 
for completely eradicating HIV. METHODS: A cost-effectiveness analysis of a par-
tially effective HIV vaccine in combination with pre-exposure prophylaxis (PrEP) 
for high risk people was performed from the perspective of a United States (US) 
healthcare payer using a patient’s lifetime horizon. Total direct costs, infections 
averted, and quality-adjusted life years (QALY) were the study outcomes. A deci-
sion tree modeled four preventive treatment strategies for high-risk men who have 
sex with men (MSM) in San Francisco: 1) vaccine and PrEP, 2) vaccine alone, 3) PrEP 
alone, and 4) no prevention strategy. RESULTS: A vaccine was found to be most 
cost-effective and dominant prevention strategy in this analysis. The incremental 
cost-effectiveness ratio (ICER) for a vaccine and PrEP combined was $45,704 per 
QALY, falling below a $100,000 per QALY willingness-to-pay threshold. An HIV vac-
cine alone was estimated to cost the payer $6,659 per infection averted and was a 
dominant strategy compared to no preventive intervention. PrEP alone cost more 
than $1.15 million at current pricing per infection averted, and combined with a 
vaccine, the cost per infection averted was reduced to $904,326. CONCLUSIONS: 
HIV incidence was the largest factor driving the cost per infection averted and 
cost per QALY for all prevention strategies, followed by the cost of PrEP for the 
two strategies that included it. US payers should actively advocate development, 
approval, coverage, and use of a vaccine to avert new HIV infections as a more 
cost-effective strategy than current preventive methods for people at high risk of 
HIV infection in the United States.
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OBJECTIVES: We assess the tradeoffs between the costs and benefits of choosing 
alternate HIV prevention strategies, including the status-quo (current HIV testing 
with antiretroviral therapy [ART] initiation at CD4 ≤ 500), testing (expanded HIV 
testing with ART initiation at CD4 ≤ 500), test-and-treat (expanded HIV testing 
and early ART start), and PrEP (PrEP initiation by uninfected individuals) strate-
gies. METHODS: A mathematical epidemiological model is developed to simulate 
HIV incidence among 15-65 year old MSM in LAC. An economic model uses the 
epidemic model results to estimate the cost and effectiveness of 624 variants of 
the testing, test-and-treat and PrEP strategies from a societal perspective. For 
each strategy, we estimate the number of new HIV infections averted, the dis-
counted costs and quality-adjusted life years (QALYs), and the incremental cost-
effectiveness ratios. The sensitivity and robustness of the estimates are assessed 
via univariate and bootstrapping probabilistic sensitivity analyses. RESULTS: In 
the base case analysis, test-and-treat, PrEP, and testing are highly cost-effective 
relative to status-quo ($21 000, $26 000, and $27 500/QALY) and significantly reduce 
new infections. This is imputable to the preventive benefits of PrEP and early 
knowledge of infection status via testing, and the survival gains from early ART 
initiation. Thirteen strategies consisting of more aggressive test-and-treat and 
PrEP approaches trace the efficient frontier for decision making. More aggres-
sive strategies are more costly but yield better effectiveness profiles, albeit with 
diminishing returns. These results remain generally robust to uncertainty in the 
epidemic, cost, and effectiveness parameters. The relative effectiveness of PrEP is 
however sensitive to PrEP and ART adherence and initiation rates. CONCLUSIONS: 
PrEP and test-and-treat strategies are cost-effective alternatives to the status-quo 
for HIV prevention among LAC MSM. When affordable, aggressive combinations 
of these strategies should be implemented. The effectiveness of these strategies 
could be enhanced with greater adherence to ART and PrEP.
